Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | RBP4 | P02753 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29707341 | 1.00 | BACE1 (0.54) | BACE1ALDH1A1HPGDUSP30L3MBTL1 | |
| SCHEMBL24126134 | 0.94 | ALDH1A1 (0.51) | BACE1ALDH1A1HPGDUSP30L3MBTL1 | |
| SCHEMBL30830777 | 0.89 | GPR119 (0.48) | BACE1ALDH1A1HPGDUSP30L3MBTL1 | |
| SCHEMBL22532774 | 0.86 | SMN1; SMN2 (0.56) | ALDH1A1HPGDL3MBTL1MAPTTSHR | |
| SCHEMBL24669559 | 0.86 | USP30 (0.56) | BACE1ALDH1A1HPGDUSP30L3MBTL1 | |
| SCHEMBL29803703 | 0.86 | USP30 (0.56) | BACE1ALDH1A1HPGDUSP30L3MBTL1 | |
| SCHEMBL14852526 | 0.85 | BACE1 (0.59) | BACE1ALDH1A1MAPTTSHRMEN1 | |
| SCHEMBL3929365 | 0.85 | L3MBTL1 (0.55) | ALDH1A1HPGDL3MBTL1MAPTTSHR | |
| SCHEMBL4951947 | 0.85 | ESR2 (0.52) | ALDH1A1HPGDUSP30L3MBTL1MAPT | |
| SCHEMBL15775206 | 0.85 | BACE1 (0.55) | BACE1ALDH1A1HPGDMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12570650-B2 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | AURIGENE ONCOLOGY LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20260028346-A1 | BTK DEGRADER AND USE THEREOF | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| US-20260028345-A1 | BTK DEGRADER AND USE THEREOF | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4543887-A2 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | Arizona Board of Regents on behalf of The University of Arizona (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025080753-A1 | DYRK/CLK PROTACS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025061035-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 南京再明医药有限公司 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2015088045-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015088045-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-18 | — | — | WO | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| WO-2014160203-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160203-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2003028728-A1 | 4-(4-SUBSTITUTED PIPERAZINYL-1YL)-BUTYLCARBOXAMIDES AS D3 DOPAMINE SUBTYPE SELECTIVE LIGANDS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028345-A1 | BTK DEGRADER AND USE THEREOF | BTK, SYK, TEC | BACE1 1507/4885ALDH1A1 4844/4885HPGD 3455/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | BACE1 2494/4885ALDH1A1 2085/4885HPGD 2098/4885 |
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | BACE1 1412/4885ALDH1A1 4568/4885HPGD 1612/4885 |
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | SMARCA2, SMARCE1, SMARCA1 | BACE1 3692/4885ALDH1A1 3952/4885HPGD 4382/4885 |
| US-20150038488-A1 | SYK INHIBITORS | SYK, BTK, LYN | BACE1 1635/4885ALDH1A1 4200/4885HPGD 4482/4885 |
| US-20260028346-A1 | BTK DEGRADER AND USE THEREOF | BTK, SYK, LYN | BACE1 908/4885ALDH1A1 4820/4885HPGD 3560/4885 |
| US-12570650-B2 | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders | SMARCC1, SMARCC2, SMARCA1 | BACE1 3262/4885ALDH1A1 1002/4885HPGD 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.